Yet Another bispecific, humanized IgG1 antibody that's under investigation is zenocutuzumab (MCLA-128), which acts through two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 features by way of a ‘dock and block’ mechanism whereby a single arm with the antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/